NCT00551590View on ClinicalTrials.gov

Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

September 30, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Placebo tablet

placebo PO (placebo control for sitagliptin) for three days

DRUG

Sitagliptin tablet

Sitagliptin 100 mg PO for three days.

DRUG

Saline infusion

Saline IV (placebo control for exendin(9-39)) on two consecutive study days

DRUG

Exendin(9-39) infusion

Exendin(9-39) IV on two consecutive study days.

Trial Locations (1)

81377

Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich, Munich

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ludwig-Maximilians - University of Munich

OTHER

NCT00551590 - Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter